Nektar Therapeutics began a quiet period on September 8, 2026, lasting until it publicly announces data from the 24-week off-treatment follow-up of its Phase 2b REZOLVE-AA study. The defined endpoint matters to investors because the data announcement will mark the end of the restricted communications period.
Key Highlights
- Nektar said the quiet period follows the approach used during prior Phase 2b REZOLVE study data disclosures.
- The communications restriction will remain in place until the follow-up data is publicly announced.
- Nektar is preparing to publicly announce follow-up results from the REZOLVE-AA study.
- REZOLVE-AA is a Phase 2b investigation of rezpegaldesleukin in severe-to-very-severe alopecia areata.
REZOLVE-AA Follow-Up Data Sets the Endpoint
The quiet period applies while Nektar (NASDAQ: NKTR) prepares for the public announcement of results from the follow-up period. The study is a Phase 2b investigation of rezpegaldesleukin for severe-to-very-severe alopecia areata. The company has not stated a separate end date. Instead, the quiet period will continue until the follow-up data is publicly announced.
Public Data Announcement Will End Quiet Period
That announcement will end the quiet period, according to Nektar’s disclosure. The update therefore links the communications restriction directly to the planned REZOLVE-AA data release.
FAQs
Q: When did Nektar Therapeutics begin its REZOLVE-AA quiet period?
A: Nektar Therapeutics began the quiet period on September 8, 2026. It relates to the planned public announcement of follow-up data from the Phase 2b REZOLVE-AA study.
Q: What does the REZOLVE-AA study evaluate?
A: The REZOLVE-AA study is a Phase 2b investigation of rezpegaldesleukin for severe-to-very-severe alopecia areata. The disclosure ties the quiet period to the planned public announcement of its follow-up data.
Q: What is the REZOLVE-AA study evaluating?
A: REZOLVE-AA is a Phase 2b investigation of rezpegaldesleukin. The study focuses on severe-to-very-severe alopecia areata.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.